全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

32P敷贴联合马来酸噻吗洛尔治疗婴幼儿皮肤血管瘤的临床研究
Clinical Research of 32P Application Combined with Timolol Maleate in the Treatment of Infantile Cutaneous Hemangioma

DOI: 10.12677/ACM.2020.108249, PP. 1663-1670

Keywords: 32P敷贴,马来酸噻吗洛尔,婴幼儿皮肤血管瘤,非选择性β受体阻滞剂,临床研究
32P Application
, Timolol Maleate, Infantile Cutaneous Hemangioma, Non-Selective Beta Blocker, Clinical Study

Full-Text   Cite this paper   Add to My Lib

Abstract:

目的:本研究拟探讨32P敷贴联合马来酸噻吗洛尔治疗婴幼儿皮肤血管瘤的价值,并且进一步评估该联合作用在治愈效果方面的优势比。方法:本研究收集本医院0~6岁被诊断为皮肤血管瘤的患者80例,详细记录患者的性别、年龄等基本情况。将患者随机分为4组,第一组采取口服非选择性β受体阻滞剂进行治疗(n = 20),第二组采取32P敷贴进行治疗(n = 20),第三组采取马来酸噻吗洛尔外敷进行治疗(n = 20),第四组采取32P敷贴联合马来酸噻吗洛尔外敷进行治疗(n = 20)。采用皮尔逊卡方检验、斯皮尔曼检验比较治愈方式与治愈效果进行相关性分析。采用单因素logistic回归分析计算临床参数对皮肤血管瘤治愈效果的比值比(odd ratio, OR)。结果:不同的治疗方式间的治疗效果具有统计学意义(P = 0.003)。在32P敷贴联合马来酸噻吗洛尔外敷组中,治愈率达到70.0%;在马来酸噻吗洛尔外敷组,治愈率达到55.0%;单独32P敷贴治疗组中,治愈率达到45.0%;在非选择性β受体阻滞剂组中,治愈率达到25.0%。在不同的治疗方式中,与非选择性β受体阻滞剂相比,32P敷贴(OR = 0.407, 95% CI: 0.106~1.559, P = 0.190),马来酸噻吗洛尔外敷(OR = 0.273, 95% CI: 0.071~1.043, P = 0.058)对治愈效果无显著影响,然而32P敷贴联合马来酸噻吗洛尔(OR = 0.143, 95% CI: 0.035~0.575, P = 0.006)对皮肤血管瘤的治愈效果具有显著的优势意义。通过特征性工作曲线(receiver operating characteristic curve,简称ROC曲线)分析得出,治疗方式与皮肤血管瘤治愈效果的关联度很强(AUC = 0.681, P = 0.005)。结论:32P敷贴联合马来酸噻吗洛尔可以提高婴幼儿皮肤血管瘤的治愈率和治疗效果。
Purpose: The purpose of this study was to investigate the value of 32P application combined with timolol maleate in the treatment of infantile cutaneous hemangioma, and to further evaluate the preponderance of the combined effect on the curative effect. Methods: In this study, 80 patients aged 0~6 years who were diagnosed with cutaneous hemangioma in our hospital were collected, and their basic information such as gender and age were recorded in detail. Patients were randomly divided into four groups: the first group was treated with oral non-selective -blocker (n = 20); the second group was treated with 32P application (n = 20); the third group was treated with timolol maleate external application (n = 20); the fourth group was treated with 32P application combined with timolol maleate external application (n = 20). Pearson chi-square test and Spielman test were used to compare the therapeutic methods and curative effects. The odd ratio (OR) of clinical parameters for the curative effect of cutaneous hemangioma was calculated by single factor Logistic regression analysis. Results: The therapeutic effect of different treatment methods was statistically significant (P = 0.003). In 32P application combined with timolol maleate external application group, the cure rate reached 70.0%. In timolol maleate external application group, the cure rate reached 55.0%. In the 32P group alone, the cure rate reached 45.0%. In the non-selective beta blocker group, the cure rate was 25.0%. Compared with non-selective beta blockers, 32P application (OR = 0.407, 95% CI: 0.106~1.559, P = 0.190) and timolol maleate external application (OR = 0.273, 95% CI: 0.071~1.043, P = 0.058) had no significant effect on the curative

References

[1]  Sipkova, Z., Xue, K., Mudhar, H.S., Wagner, B. and Hildebrand, G.D. (2018) Early and Late Histological and Ultrastructural Findings in Resected Infantile Capillary Hemangiomas Following Treatment with Topical Beta-Blocker Timolol Maleate 0.5. Ocular Oncology and Pathology, 4, 100-106.
https://doi.org/10.1159/000477411
[2]  Darrow, D.H., Greene, A.K., Mancini, A.J. and Nopper, A.J. (2015) Diagnosis and Management of Infantile Hemangioma: Executive Summary. Pediatrics, 136, 786-791.
https://doi.org/10.1542/peds.2015-2482
[3]  Hoover, L. (2019) Infantile Hemangioma: AAP Releases Guideline for Management. American Family Physician, 100, 186-187.
[4]  Howard, M.A., Olitsky, S.E., Rychwalski, P. and Mungan, N. (2019) Management of Periocular Infantile Hemangioma. Journal of Pediatric Ophthalmology and Strabismus, 56, 344-346.
https://doi.org/10.3928/01913913-20190826-01
[5]  Painter, S.L. and Hildebrand, G.D. (2016) Review of Topical Beta Blockers as Treatment for Infantile Hemangiomas. Survey of Ophthalmology, 61, 51-58.
https://doi.org/10.1016/j.survophthal.2015.08.006
[6]  Al-Haddad, C., et al. (2019) β-Blockers in the Treatment of Periocular Infantile Hemangioma. Current Opinion in Ophthalmology, 30, 319-325.
https://doi.org/10.1097/ICU.0000000000000591
[7]  Moyakine, A.V., Herwegen, B. and van der Vleuten, C.J.M. (2017) Use of the Hemangioma Severity Scale to Facilitate Treatment Decisions for Infantile Hemangiomas. Journal of the American Academy of Dermatology, 77, 868-873.
https://doi.org/10.1016/j.jaad.2017.06.003
[8]  Hernandez-Martin, S., Lopez-Gutierrez, J.C., Lopez-Fernandez, S., et al. (2012) Brain Perfusion SPECT in Patients with PHACES Syndrome under Propranolol Treatment. European Journal of Pediatric Surgery, 22, 54-59.
https://doi.org/10.1055/s-0031-1291300
[9]  Zhang, L., Wu, H.W., Yuan, W. and Zheng, J.W. (2017) Propranolol Therapy for Infantile Hemangioma: Our Experience. Drug Design, Development and Therapy, 11, 1401-1408.
https://doi.org/10.2147/DDDT.S134808
[10]  Püttgen, K., Lucky, A., Adams, D., et al. (2016) Topical Timolol Maleate Treatment of Infantile Hemangiomas. Pediatrics, 138, e20160355.
https://doi.org/10.1542/peds.2016-0355
[11]  Wu, Q., Shi, Q., Long, J., Li, J., Guo, Y. and Lei, S. (2017) Usage and Efficacy of Timolol Maleate Eye Drops in Treatment of Superficial Infantile Hemangioma. Journal of Central South University. Medical Sciences, 42, 657-661.
[12]  Borok, J., Gangar, P., Admani, S., Proudfoot, J. and Friedlander, S.F. (2018) Safety and Efficacy of Topical Timolol Treatment of Infantile Haemangioma: A Prospective Trial. British Journal of Dermatology, 178, e51-e52.
https://doi.org/10.1111/bjd.15865
[13]  Kim, K.H., Choi, T.H., Choi, Y., et al. (2017) Comparison of Efficacy and Safety between Propranolol and Steroid for Infantile Hemangioma: A Randomized Clinical Trial. JAMA Dermatology, 153, 529-536.
https://doi.org/10.1001/jamadermatol.2017.0250
[14]  Léaute-Labrèze, C., Boccara, O., Degrugillier-Chopinet, C., et al. (2016) Safety of Oral Propranolol for the Treatment of Infantile Hemangioma: A Systematic Review. Pediatrics, 138, e20160353.
https://doi.org/10.1542/peds.2016-0353
[15]  Porubanova, M., Sharashidze, A., Hornova, J. and Gerinec, A. (2015) β-Blockers in the Treatment of Periocular Infantile Capillary Haemangioma. Neoplasma, 62, 974-979.
https://doi.org/10.4149/neo_2015_118
[16]  Ramtohul, P., Beylerian, M., Dambricourt, L., Matonti, F. and Denis, D. (2019) Secondary Congenital Glaucoma Associated with Retro-Orbital Infantile Hemangioma: A Masquerade Syndrome. Journal of Glaucoma, 28, e103-e106.
https://doi.org/10.1097/IJG.0000000000001227
[17]  Chim, H., Armijo, B.S., Miller, E., Gliniak, C., Serret, M.A. and Gosain, A.K. (2012) Propranolol Induces Regression of Hemangioma Cells through HIF-1α-Mediated Inhibition of VEGF-A. Annals of Surgery, 256, 146-156.
https://doi.org/10.1097/SLA.0b013e318254ce7a
[18]  Korpisalo, P., Hyt?nen, J.P., Laitinen, J.T., et al. (2014) Ultrasound Imaging with Bolus Delivered Contrast Agent for the Detection of Angiogenesis and Blood Flow Irregularities. American Journal of Physiology: Heart and Circulatory Physiology, 307, H1226-H1232.
https://doi.org/10.1152/ajpheart.00315.2013
[19]  Painter, S.L. and Hildebrand, G.D. (2016) Topical Timolol Maleate 0.5% Solution for the Management of Deep Periocular Infantile Hemangiomas. Journal of AAPOS, 20, 172-174.e1.
https://doi.org/10.1016/j.jaapos.2015.11.012
[20]  Filippi, L., Dal Monte, M., Casini, G., Daniotti, M., Sereni, F. and Bagnoli, P. (2015) Infantile Hemangiomas, Retinopathy of Prematurity and Cancer: A Common Pathogenetic Role of the β-Adrenergic System. Medicinal Research Reviews, 35, 619-652.
https://doi.org/10.1002/med.21336
[21]  Ganti, A.K., Ray, J., Mooney, K.L., Zambrano, E., Pja, H. and Fok, W. (2019) Unusual Cause of Pediatric Vaginal Bleeding: Infantile Capillary Hemangioma of the Cervix. Journal of Pediatric and Adolescent Gynecology, 32, 80-82.
https://doi.org/10.1016/j.jpag.2018.08.003
[22]  Wang, J., Li, N., Fan, Y., Yang, N. and Xia, L. (2019) Primary Extranodal Natural Killer/T-Cell Nasal-Type Lymphoma of Spine: A Case Report. Medicine (Baltimore), 98, e17661.
https://doi.org/10.1097/MD.0000000000017661
[23]  Bornfeld, N. and Kreusel, K.M. (2007) Capillary Hemangioma of the Retina in Cases of Von Hippel-Lindau Syndrome. New Therapeutic Directions. Ophthalmologe, 104, 114-118.
https://doi.org/10.1007/s00347-007-1485-1

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133